Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
151-165 of 312
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast CancerClinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerDESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
On the Frontlines of Metastatic Breast CancerImproving Metastatic Breast Cancer Care Through Integrated Palliative Support
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®Diagnosing LCNEC of the Lung: Challenges and Strategies
- advertisement
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®Personalizing Care for Large Cell Neuroendocrine Carcinoma
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
- advertisement
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
Project Oncology®Investigating the Impact of Exercise on Cancer Immunotherapy Outcomes
